AbbVie
Price
Price
Historical dividends and forecast
AbbVie has so far distributed $6.20 in 2024. The next dividend will be paid on 14.02.2025
CHART BY
Frequently asked questions
What is AbbVie's market capitalization?
What is AbbVie's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for AbbVie?
What are the analyst ratings and target price for AbbVie's stock?
What is AbbVie's revenue over the trailing twelve months?
Is AbbVie paying dividends?
What is the EBITDA for AbbVie?
What is the free cash flow of AbbVie?
What is the 5-year beta of AbbVie's stock?
How many employees does AbbVie have, and what sector and industry does it belong to?
What is the free float of AbbVie's shares?
Financials
Market Cap
$296.46B5Y beta
0.57EPS (TTM)
$2.866Free Float
1.77BP/E ratio (TTM)
58.53Revenue (TTM)
$55.53BEBITDA (TTM)
$23.98BFree Cashflow (TTM)
$4.72BPricing
Analyst Ratings
The price target is $185.36 and the stock is covered by 28 analysts.
Buy
20
Hold
8
Sell
0
Information
AbbVie Inc. is a diversified research-based biopharmaceutical company engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. It offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383 for the treatment of inflammatory bowel disease.
50,000
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker